Takeda Ventures converted debt financing into equity through the genetic medicine developer's latest round, which was led by strategic partner AnGes.
Biopharmaceutical company AnGes led a $61m series B round for US-based gene-editing technology developer Emendo Biotherapeutics on Wednesday.
The round included an undisclosed amount of convertible note financing provided by pharmaceutical firm Takeda’s investment arm, Takeda Ventures, in April 2019 which was converted to equity. Healthcare investment firm OrbiMed also invested, as did its OrbiMed Israel Partners offshoot.
Emendo’s technology platform, Omni, combines Crispr gene-editing with protein engineering to create drugs intended to treat disorders including severe congenital neutropenia, where…
